Although ATM mutations are present in approximately 14% of CRC patients, the precise mechanisms of action of PARP inhibitors, particularly BMN673, in ATM-deficient CRC are not fully elucidated, especially the impact of potent PARP-trapping on DNA repair pathway rewiring [12]. Here, ATM is linked to colorectal carcinoma.